Merger with Eli Lilly receives key antitrust approvals

AtaiBeckley Inc. reported significant progress in its merger with Eli Lilly and Company, specifically regarding antitrust approvals. The waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act for the merger expired at 11:59 p.m. Eastern Time on August 28, 2026.

Additionally, the United Kingdom's Competition and Markets Authority (CMA) indicated on August 21, 2026, that it had no further questions concerning the merger. This response followed a briefing paper submitted by Eli Lilly. These developments mark key milestones in satisfying regulatory conditions for the transaction.

Further good news came from the Australian Competition and Consumer Commission, which determined on August 27, 2026, that the merger could be consummated. This approval is subject to a 14-calendar day waiting period, which is set to expire at 10:00 a.m. Eastern Time on September 10, 2026.

The merger agreement between AtaiBeckley Inc. and Eli Lilly and Company, including its indirect wholly owned subsidiary Albali Acquisition Corporation, was initially entered into on July 15, 2026. The completion of these antitrust reviews brings the company closer to the finalization of this agreement, where AtaiBeckley Inc. will become a wholly owned subsidiary of Eli Lilly and Company.